Specifically, we observed NDRG1 amplification in 23% of breast cancer samples, whereas NDRG2 was amplified in 0.9% cases, NDRG3 in 2.5% and NDRG4 in 0.3% (Figure 4B) [93,94,95]. This evidence concerns the gene NDRG3 and breast carcinoma.